今朝、アメリカ糖尿病学会から送られてきたメールの内容です。今月号のDiabetes Care、アメリカ糖尿病学会雑誌のトピックスは、

1．脂肪肝
2．Closed Loop Insulin pump
3.  ディジタルアプリ（治療に必要なデジタル教育やツールなど）
などでした。

私がとりあげた、抗肥満薬で脂肪肝をとるアイディアや、Closed Loop pumpのアイディア、さらには、こうしたSNSやサイトを利用したデジタル患者教育が、やはり世界の最先端の話題になっているようです。今後も世界の最先端をキャッチアップしていこうと考えます。読者の皆さんのみならず、当院の糖尿病療養士スタッフたちへの「学習」にも役立っています。

鈴木吉彦

☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆

Diabetes Care Welcomes 2020 With New Special-Topic Collections and
Updated Guidance for Clinical Practice

Diabetes Care, the premier clinical research journal of the American Diabetes Association® (ADA), is ushering in 2020 with two timely special-topic article collections, important updates to key clinical practice guidelines, and a new consensus report on diabetes digital applications (apps).

A special-topic collection in the February issue focuses on nonalcoholic fatty liver disease (NAFLD). Its centerpiece is an article presenting staggering results from the most comprehensive effort to date to quantify the clinical and economic burden of liver disease in people with type 2 diabetes. The overall prevalence of NAFLD is estimated to be >70%, affecting >18 million patients with type 2 diabetes, and the 20-year economic burden from the subgroup having both prevalent nonalcoholic steatohepatitis (the more severe form of NAFLD) and type 2 diabetes is estimated at $642 billion. Other articles in the collection examine the effects of exercise on liver fat in children, the sodium–glucose cotransporter 2 inhibitor empagliflozin as a potential treatment for fatty liver in type 2 diabetes, and an evaluation showing the shortcomings of all current diagnostic panels and plasma biomarkers used to identify NAFLD.

Continuous glucose monitoring (CGM) in type 1 diabetes is the topic of another special collection, published in the January issue. These articles address questions such as who stands to benefit most from CGM use, when and how best to implement it, and which outcomes are most crucial to monitor and improve. The collection includes three descriptions of CGM experiences in diverse populations, three reports describing research applications of CGM, and an article of great interest showing that CGM use can substantially reduce hyperglycemia without increasing the risk of severe hypoglycemia in adults with type 1 diabetes.

An ADA/European Association for the Study of Diabetes (EASD) consensus report on digital diabetes apps was also published in the January issue of Diabetes Care. This statement reviews the current landscape of digital apps for diabetes and the lack of oversight and regulation of such programs. The statement brings to light several important issues that the greater diabetes community needs to address to ensure the safety and success of diabetes-related apps and recommends actions to resolve some of the current problems.